Adverum Biotechnologies Missed Consensus Estimates

Adverum Biotechnologies (ADVM) reported a loss of $2.25 per share on revenue of $0.00 million for the first quarter ended March 2025. The consensus estimate was a loss of $1.92 per share on revenue of $0.95 million. The company missed consensus estimates by 17.19%.

Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum?s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control.